Therapy Acceleration Program

A strategic initiative to accelerate the development of innovative blood cancer treatments, supportive care and diagnostics.

The Therapy Acceleration Program® (TAP) identifies and funds innovative projects related to therapies, supportive care or diagnostics that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need.

TAP funding assists both clinical investigators and companies in gaining critical clinical proof of concept data that better enables them to obtain the resources they need or a partner to complete the testing, registration and marketing of new treatments, supportive care and diagnostics for leukemia, lymphoma and myeloma.

Latest News

  • Affimed has initiated a phase 2a clinical trial (NCT02321592) in Hodgkin lymphoma, or HL for its lead candidate, AFM13, a bispecific CD30/CD16A TandAb antibody, with first data expected in late 2015 and final data expected in the second half of 2016. Affimed is preparing an additional phase 1b/2a investigator-initiated trial with AFM13 in CD30-positive lymphoma as well as a phase 1b trial with AFM13 in combination with a checkpoint modulator. Initial evidence of the synergistic effect of AFM13 in combination with checkpoint modulators will be presented at the upcoming ASCO 2015 Annual Meeting.

  • OXiGENE, Inc. a biopharmaceutical company developing novel therapies for the treatment of cancer, announced on May 29, 2015 that the U.S. Patent and Trademark Office has granted it a patent (U.S. Patent No. 9,040,500) related to the use of OXi4503 for the treatment of myeloid neoplasms, including acute myeloid leukemia (AML). The study (NCT01085656) is sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program and is being led by Dr. Chris Cogle at the University of Florida.

  • Acetylon initiated a Phase 1a/b study of ACY-241 in combination with Pomalyst® in relapsed or relapsed-and-refractory multiple myeloma (NCT02400242).

  • Acetylon presented data on synergistic activity of selective HDAC6 inhibition in preclinical models of multiple myeloma and mantle cell lymphoma at the AACR 2015 Annual Meeting.

  • Researchers at Johns Hopkins announced significant findings in Science Translational Medicine about a novel approach to immunotherapy to treat patients with myeloma. A Phase 2 study (NCT01858558) is currently enrolling and is being supported through the Therapy Acceleration Program. 

  • Nanosyn and The Leukemia & Lymphoma Society Announce Achieving a Significant Milestone in Developing New Therapies for MLL Leukemia

  • Kura Oncology’s Menin-Mll Inhibitor Program Shows Promise In Study Published In Cancer Cell; Program Targeting Acute Leukemias Licensed From University Of Michigan

Clinical Trials in Partnership with LLS

Both TAP and LLS research grant fundings are critical in supporting many active clinical trials at any given time. The ClinicalTrials.gov website provides an updated listing of clinical trials where LLS is listed as a collaborator. ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. More information about the clinical trials in partnership with LLS TAP can also be found within each TAP division found below.

How TAP Works

The program comprises three divisions, each with designated strategies, to speed the development of blood cancer treatments, supportive care and diagnostics:

TAP Divisions

Academic Concierge Division

The Academic Concierge Division capitalizes on LLS's academic grant-supported portfolio of development-stage projects. This division supports the further development of selected academic projects (with or without prior LLS grant support) to gain clinical proof of concept. Successful projects will potentially be advanced for further clinical development by creating additional partnerships with pharmaceutical...

Biotechnology Accelerator Division

The Biotechnology Accelerator Division identifies companies developing novel anti-cancer therapies, supportive care or diagnostics and co-funds specific projects that will enable a company to partner or raise additional funding to complete the testing, registration and marketing of new therapies or diagnostics for blood cancer indications.

Clinical Trials Division

The Clinical Trials Division was created to help patients gain easier access to clinical trials in the community and familiar settings and to address the bottleneck of clinical trials – patient enrollment rate. In June 2013 the Blood Cancer Research Partnership (BCRP) was established together with the Dana-Farber Cancer Institute in Boston with TAP funding. BCRP aims to accelerate the advancemen...